219843-76-2

Basic information

• Product Name: Androst-16-en-3-ol, 17-(3-pyridinyl)-, acetate (ester),(3β,5α)-
• Synonyms: Androst-16-en-3-ol, 17-(3-pyridinyl)-, acetate (ester),(3β,5α)-;(8R,9S,10S,13S,14S)-10,13-dimethyl-17-(pyridin-3-yl)-2,3,4,5,6,7,8,9,10,11,12,13,14,15-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate;5,6-Dihydroabiraterone Acetate
• CAS NO: 219843-76-2
• Molecular Formula: C26H35NO2
• Molecular Weight: 393.5616
• Mol File: 219843-76-2.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: Androst-16-en-3-ol, 17-(3-pyridinyl)-, acetate (ester),(3β,5α)-(CAS DataBase Reference)
• NIST Chemistry Reference: Androst-16-en-3-ol, 17-(3-pyridinyl)-, acetate (ester),(3β,5α)-(219843-76-2)
• EPA Substance Registry System: Androst-16-en-3-ol, 17-(3-pyridinyl)-, acetate (ester),(3β,5α)-(219843-76-2)

Safety Data

• Hazardous Substances Data: 219843-76-2(Hazardous Substances Data)

Usage

Uses

5,6-Dihydroabiraterone Acetate is used in the preparation and activity of abirateron metabolites, redirecting abiraterone metabolite to fine-tune prostate cancer anti-androgen therapy.

Upstream product

• 91934-55-3 3β-acetoxy-5α-androsta-16-ene-17-yl trifluoromethanesulfonate 
• 89878-14-8 3-Diethylboranylpyridine 
• 481-29-8 Epiandrosterone 
• 1239-31-2 3β-acetoxy-5α-androstan-17-one 
• 626-55-1 3-Bromopyridine 
• 10481-80-8 3β-hydroxy-17-hydrozone-5α-androstane 
• 53-43-0 dehydroepiandrosterone 
• 108-24-7 acetic anhydride 
• 219843-75-1 (3β,5α)-17-(3'-pyridinyl)androst-16-en-3-ol 

Downstream Products

• 154229-25-1 17-(3-pyridyl)-5α-androsta-16-ene-3α-ol 
• 154229-26-2 17-(3-pyridyl)-5α-androsta-16-ene-3-one 
• 219843-75-1 (3β,5α)-17-(3'-pyridinyl)androst-16-en-3-ol 

Relevant articles and documents

Abiraterone acetate reducing impurity and preparation method thereof

The invention discloses an abiraterone acetate reducing impurity and a preparation method thereof. The impurity is 17-(3-pyridyl) androstane-3 beta-acetoxyl. The preparation method of the impurity includes the steps: taking dehydroepiandrosterone as a starting material; performing catalytic hydrogenation by palladium carbon to obtain (3 beta)-3-hydroxy-17-sterone; performing reaction by hydrazine hydrate to obtain 17-hydrazono-androstane-3 beta-alcohol; performing iodine substitution to obtain 17-iodine-androstane-3 beta-alcohol; reacting the 17-iodine-androstane-3 beta-alcohol with borane reagents under palladium catalysis to obtain 17-(3-pyridyl) androstane-3 beta-alcohol; performing acetic anhydride acetylation to obtain the abiraterone acetate reducing impurity 17-(3-pyridyl) androstane-3 beta-acetoxyl.

ALTERING STEROID METABOLISM FOR TREATMENT OF STEROID-DEPENDENT DISEASE

A method of treating steroid-dependent disease such as prostate cancer in a subject is described that includes administering a therapeutically effective amount a CYP17A inhibitor and an effective amount of a 5- -reductase inhibitor to the subject.